CapsoVision (CV) Return on Capital Employed (2025 - 2026)

CapsoVision (CV) posted Return on Capital Employed of 141.65% for Q4 2025, up 20.5% sequentially from 178.17% in Q3 2025.

CapsoVision (CV) Return on Capital Employed (2025 - 2026) Analysis & Trends

CapsoVision has reported Return on Capital Employed for 1 years, with the latest figure at 141.65% in Q4 2025.

Quarterly Return on Capital Employed changed N/A year-over-year to 141.65% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 141.65% (changed N/A YoY) and the FY2025 annual result came in at 195.43%, changed N/A from the prior year.
Return on Capital Employed climbed to 141.65% in Q4 2025 per CV's latest filing, from 178.17% in the prior quarter.
Over five years, Return on Capital Employed peaked at 141.65% in Q4 2025 and troughed at 227.37% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	7.98%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	13.69%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	8.02%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	10.83%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	11.99%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	27.21%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	9.47%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	12.84%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	12.08%
10	CapsoVision	295.13 Mn	286.05 Mn	1.87 Mn	-209.82%

Download Data